NEVRO CORP (NVRO) Stock Price, Forecast & Analysis
NYSE:NVRO • US64157F1030
NVRO Key Statistics, Chart & Performance
The current stock price of NVRO is 5.84 USD. In the past month the price increased by 0.86%. In the past year, price decreased by -56.06%.
NVRO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is one of the better performing stocks in the market, outperforming 72.33% of all stocks.
NVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVRO. Both the profitability and financial health of NVRO have multiple concerns.
NVRO Financial Highlights
Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 25.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -49.11% | ||
| Debt/Equity | 0.98 |
NVRO Forecast & Estimates
19 analysts have analysed NVRO and the average price target is 8.87 USD. This implies a price increase of 51.87% is expected in the next year compared to the current price of 5.84.
For the next year, analysts expect an EPS growth of -29.92% and a revenue growth 0.32% for NVRO
NVRO Ownership
NVRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 169.664B | ||
| SYK | STRYKER CORP | 24.21 | 139.908B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 109.921B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.358B | ||
| RMD | RESMED INC | 20.57 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 35.845B | ||
| DXCM | DEXCOM INC | 27.73 | 25.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVRO
Company Profile
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Company Info
NEVRO CORP
1800 Bridge Parkway
Redwood City CALIFORNIA 94065 US
CEO: D. Keith Grossman
Employees: 1099
Phone: 16502510005
NEVRO CORP / NVRO FAQ
What does NVRO do?
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
What is the stock price of NEVRO CORP today?
The current stock price of NVRO is 5.84 USD.
Does NEVRO CORP pay dividends?
NVRO does not pay a dividend.
How is the ChartMill rating for NEVRO CORP?
NVRO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is NEVRO CORP (NVRO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVRO.
Can you provide the market cap for NEVRO CORP?
NEVRO CORP (NVRO) has a market capitalization of 221.22M USD. This makes NVRO a Micro Cap stock.